US approves updated Pfizer, Moderna shots targeting Omicron / Photo: © AFP/File
SCS
0.0000
The China Mail - US approves updated Pfizer, Moderna shots targeting Omicron
USD
-
AED 3.672504
AFN 66.344071
ALL 83.58702
AMD 382.869053
ANG 1.789982
AOA 917.000367
ARS 1405.057166
AUD 1.540832
AWG 1.805
AZN 1.70397
BAM 1.691481
BBD 2.013336
BDT 122.007014
BGN 1.69079
BHD 0.374011
BIF 2943.839757
BMD 1
BND 1.3018
BOB 6.91701
BRL 5.332404
BSD 0.999615
BTN 88.59887
BWP 13.420625
BYN 3.406804
BYR 19600
BZD 2.010326
CAD 1.40485
CDF 2150.000362
CHF 0.80538
CLF 0.024066
CLP 944.120396
CNY 7.11935
CNH 7.12515
COP 3780
CRC 501.883251
CUC 1
CUP 26.5
CVE 95.363087
CZK 21.009504
DJF 177.720393
DKK 6.457204
DOP 64.223754
DZD 129.411663
EGP 46.950698
ERN 15
ETB 154.306137
EUR 0.86435
FJD 2.28425
FKP 0.759642
GBP 0.759936
GEL 2.70504
GGP 0.759642
GHS 10.930743
GIP 0.759642
GMD 73.000355
GNF 8677.076622
GTQ 7.659909
GYD 209.133877
HKD 7.77703
HNL 26.282902
HRK 6.514104
HTG 133.048509
HUF 332.660388
IDR 16685.5
ILS 3.24758
IMP 0.759642
INR 88.639504
IQD 1309.474904
IRR 42100.000352
ISK 126.580386
JEP 0.759642
JMD 160.439
JOD 0.70904
JPY 153.43504
KES 129.203801
KGS 87.450384
KHR 4023.264362
KMF 421.00035
KPW 899.998686
KRW 1455.990383
KWD 0.306904
KYD 0.83302
KZT 524.767675
LAK 21703.220673
LBP 89512.834262
LKR 304.684561
LRD 182.526573
LSL 17.315523
LTL 2.95274
LVL 0.60489
LYD 5.458091
MAD 9.265955
MDL 17.042585
MGA 4492.856402
MKD 53.206947
MMK 2099.464216
MNT 3582.836755
MOP 8.007472
MRU 39.595594
MUR 45.910378
MVR 15.405039
MWK 1733.369658
MXN 18.44605
MYR 4.176039
MZN 63.950377
NAD 17.315148
NGN 1436.000344
NIO 36.782862
NOK 10.153804
NPR 141.758018
NZD 1.777162
OMR 0.38142
PAB 0.999671
PEN 3.37342
PGK 4.220486
PHP 58.805504
PKR 282.656184
PLN 3.665615
PYG 7072.77311
QAR 3.643196
RON 4.398804
RSD 102.170373
RUB 80.869377
RWF 1452.42265
SAR 3.750713
SBD 8.230592
SCR 13.652393
SDG 600.503676
SEK 9.528504
SGD 1.301038
SHP 0.750259
SLE 23.203667
SLL 20969.499529
SOS 571.228422
SRD 38.599038
STD 20697.981008
STN 21.189281
SVC 8.746265
SYP 11056.879504
SZL 17.321588
THB 32.395038
TJS 9.226139
TMT 3.51
TND 2.954772
TOP 2.342104
TRY 42.211304
TTD 6.77604
TWD 30.981804
TZS 2455.000335
UAH 41.915651
UGX 3498.408635
UYU 39.809213
UZS 12055.19496
VES 228.194038
VND 26310
VUV 122.189231
WST 2.820904
XAF 567.301896
XAG 0.020684
XAU 0.00025
XCD 2.70255
XCG 1.801521
XDR 0.707015
XOF 567.306803
XPF 103.14423
YER 238.503589
ZAR 17.29905
ZMK 9001.203584
ZMW 22.615629
ZWL 321.999592
- McKenzie ends Scotland dream of first win over New Zealand
- McKenzie stars as New Zealand inflict heartbreak upon Scotland
- De Ligt rescues Man Utd in Spurs draw, Arsenal aim to extend lead
- Kane saves Bayern but record streak ends at Union
- Bolivia's new president takes over, inherits economic mess
- Edwards set for Wolves job after Middlesbrough allow talks
- COP30: Indigenous peoples vital to humanity's future, Brazilian minister tells AFP
- Marquez wins Portuguese MotoGP sprint race
- Saim, Abrar star in Pakistan's ODI series win over South Africa
- Norris extends title lead in Sao Paulo GP sprint after Piastri spin
US approves updated Pfizer, Moderna shots targeting Omicron
US health officials on Wednesday authorized updated Covid-19 vaccinations by Moderna and Pfizer-BioNTech that specifically target the latest strains of the Omicron variant, with the goal of jump-starting a new booster campaign.
The two updated booster shots aimed at providing "better protection against Covid-19 caused by the Omicron variant" are approved for people age 12 and above for the Pfizer shot and 18 and older for Moderna, the Food and Drug Administration (FDA) said in a statement.
This new generation of anti-Covid vaccines targets both the original strain of coronavirus and the BA.4 and BA.5 lineages, the subvariants of Omicron that are causing the most cases in the United States and which the FDA predicts will circulate in the coming months.
Earlier this summer the US health department announced it had purchased 105 million doses from Pfizer and 66 million from Moderna for use over the fall and winter.
The vaccines have yet to be recommended by the Centers for Disease Control and Prevention, the nation's health protection agency. But an independent panel of experts is scheduled to be convened by the CDC on Thursday to discuss the updates.
CDC director Rochelle Walensky will be in charge of giving the final green light.
The new versions of the vaccines could potentially be available in the United States as early as next week.
"Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings," Moderna chief executive Stephane Bancel said in a statement.
The vaccines currently in circulation target the initial strain of the virus that first appeared in Wuhan, China. But they have gradually proven to be less effective against the variants that have appeared over time, due to rapid evolution of the virus.
In contrast to the Alpha and Delta variants, which eventually waned, Omicron and its subvariants have come to dominate infections worldwide in 2022.
Pfizer and Moderna have also filed for approval of their updated vaccines with the European Medicines Agency.
A.Kwok--ThChM
